Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7500277rdf:typepubmed:Citationlld:pubmed
pubmed-article:7500277lifeskim:mentionsumls-concept:C2611014lld:lifeskim
pubmed-article:7500277lifeskim:mentionsumls-concept:C2348532lld:lifeskim
pubmed-article:7500277lifeskim:mentionsumls-concept:C1527240lld:lifeskim
pubmed-article:7500277lifeskim:mentionsumls-concept:C2699488lld:lifeskim
pubmed-article:7500277lifeskim:mentionsumls-concept:C2585225lld:lifeskim
pubmed-article:7500277pubmed:issue8lld:pubmed
pubmed-article:7500277pubmed:dateCreated1996-1-18lld:pubmed
pubmed-article:7500277pubmed:abstractTextThe direct analytical and semipreparative high-performance liquid chromatographic (HPLC) resolution of the enantiomers of IDRA 21 [1,7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide] is reported. (+/-)-IDRA 21 administered orally to rats subjected to a water maze cognition test elicited a performance enhancing effect. Between the two enantiomers, (+)-IDRA 21 was identified as being pharmacologically active in the water maze performance test, whereas (-)-IDRA 21 was completely devoid of activity when given in doses comparable to those of the dextrorotatory (+)-enantiomer. The design and preparation of a new chiral stationary phase (CSP) employed for the liquid chromatographic resolution of the enantiomers of racemic IDRA 21 is presented. This brush-type CSP, which has not been described before, is a "mixed" (pi-donor pi-acceptor) type and is derived from (R)-N-(3,5-dinitrobenzoyl) allylglycine 2,6-dimethylanilide. It is easily prepared and possesses a relatively broad scope of applicability, as determined by its ability to resolve the enantiomers of both pi-acidic and pi-basic compounds.lld:pubmed
pubmed-article:7500277pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7500277pubmed:languageenglld:pubmed
pubmed-article:7500277pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7500277pubmed:citationSubsetIMlld:pubmed
pubmed-article:7500277pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7500277pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7500277pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7500277pubmed:statusMEDLINElld:pubmed
pubmed-article:7500277pubmed:monthAuglld:pubmed
pubmed-article:7500277pubmed:issn0022-3549lld:pubmed
pubmed-article:7500277pubmed:authorpubmed-author:CostaEElld:pubmed
pubmed-article:7500277pubmed:authorpubmed-author:GuidottiAAlld:pubmed
pubmed-article:7500277pubmed:authorpubmed-author:PirkleW HWHlld:pubmed
pubmed-article:7500277pubmed:authorpubmed-author:UzunovD PDPlld:pubmed
pubmed-article:7500277pubmed:authorpubmed-author:ZivkovichIIlld:pubmed
pubmed-article:7500277pubmed:issnTypePrintlld:pubmed
pubmed-article:7500277pubmed:volume84lld:pubmed
pubmed-article:7500277pubmed:ownerNLMlld:pubmed
pubmed-article:7500277pubmed:authorsCompleteYlld:pubmed
pubmed-article:7500277pubmed:pagination937-42lld:pubmed
pubmed-article:7500277pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:7500277pubmed:meshHeadingpubmed-meshheading:7500277-...lld:pubmed
pubmed-article:7500277pubmed:meshHeadingpubmed-meshheading:7500277-...lld:pubmed
pubmed-article:7500277pubmed:meshHeadingpubmed-meshheading:7500277-...lld:pubmed
pubmed-article:7500277pubmed:meshHeadingpubmed-meshheading:7500277-...lld:pubmed
pubmed-article:7500277pubmed:meshHeadingpubmed-meshheading:7500277-...lld:pubmed
pubmed-article:7500277pubmed:meshHeadingpubmed-meshheading:7500277-...lld:pubmed
pubmed-article:7500277pubmed:meshHeadingpubmed-meshheading:7500277-...lld:pubmed
pubmed-article:7500277pubmed:meshHeadingpubmed-meshheading:7500277-...lld:pubmed
pubmed-article:7500277pubmed:meshHeadingpubmed-meshheading:7500277-...lld:pubmed
pubmed-article:7500277pubmed:meshHeadingpubmed-meshheading:7500277-...lld:pubmed
pubmed-article:7500277pubmed:meshHeadingpubmed-meshheading:7500277-...lld:pubmed
pubmed-article:7500277pubmed:meshHeadingpubmed-meshheading:7500277-...lld:pubmed
pubmed-article:7500277pubmed:meshHeadingpubmed-meshheading:7500277-...lld:pubmed
pubmed-article:7500277pubmed:meshHeadingpubmed-meshheading:7500277-...lld:pubmed
pubmed-article:7500277pubmed:year1995lld:pubmed
pubmed-article:7500277pubmed:articleTitleEnantiomeric resolution with a new chiral stationary phase of 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide, a cognition-enhancing benzothiadiazine derivative.lld:pubmed
pubmed-article:7500277pubmed:affiliationCenter for Neuropharmacology, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.lld:pubmed
pubmed-article:7500277pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7500277pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:7500277pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7500277lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7500277lld:pubmed